ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates Portfolio News / By Karina Tin March 11, 2024
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results Portfolio News / By Karina Tin March 11, 2024
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial Portfolio News / By Karina Tin March 11, 2024
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Portfolio News / By Karina Tin March 7, 2024
Synthekine Announces Presentation of Initial Results from Phase 1a/1b Clinical Trial of STK-012 at AACR 2024 Annual Meeting Portfolio News / By Karina Tin March 7, 2024
A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer Portfolio News / By Karina Tin March 4, 2024
Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases Portfolio News / By Karina Tin February 29, 2024
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP Portfolio News / By Karina Tin February 26, 2024
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications Portfolio News / By Karina Tin February 26, 2024
Synthekine Appoints Geoff Nosrati, Ph.D., as Chief Business Officer and Announces Executive Leadership Changes Portfolio News / By Karina Tin February 21, 2024